Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

NCT02674893 on ClinicalTrials.gov · last registry update 2026-02-09

Stopped early, having planned 48 participants. The sponsor logged completion for 31 August 2016. Primary outcome, as filed: Modifications in wanting. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Centre Hospitalier Universitaire Dijon
Sponsor type: Other
Enrollment: 48
Started: 2014-02-04
Primary completion: 2016-08-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Modifications in wanting

Conditions studied

Type 2 Diabetes · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.